Diabetic peripheral neuropathy, the progressive damage to peripheral nerves caused by chronic high blood sugar, affects roughly half of people with diabetes over their lifetime and sets the stage for a cascade of devastating outcomes. When sensation in the feet is lost, minor injuries go unnoticed, wounds fail to heal, ulcers develop, and infections can burrow into bone. In the worst cases, the resulting osteomyelitis or the fragmented, inflamed joints of Charcot neuroarthropathy end in amputation. The condition is also a marker of systemic vulnerability; patients with neuropathic foot complications face substantially elevated mortality. With GLP-1 receptor agonists now prescribed to millions of people worldwide, understanding how these drugs influence the neuropathic foot has become a pressing clinical question.

Led by Fady Tawfik of Howard University College of Medicine, with colleagues at Texas A&M University College of Medicine and the University of Maryland School of Medicine, the research team turned to the TriNetX US Collaborative Network, a federated database aggregating de-identified electronic health records from dozens of American healthcare organizations. They identified adults with a diagnosis of type 2 diabetes mellitus and diabetic neuropathy, unspecified, coded under ICD-10-CM as E11.40, who had newly initiated either a GLP-1 receptor agonist or a DPP-4 inhibitor. Both drug classes act on the incretin system—the hormonal axis that amplifies insulin secretion after meals—but through different mechanisms. GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone directly and resist enzymatic breakdown, while DPP-4 inhibitors block the enzyme dipeptidyl peptidase-4 that normally degrades endogenous GLP-1, modestly prolonging its action.

Because patients prescribed these drugs often differ systematically in age, weight, kidney function, and overall disease burden, naive comparisons would be misleading. The investigators therefore applied 1:1 propensity score matching, a statistical technique that pairs each GLP-1 receptor agonist user with a DPP-4 inhibitor user who shares a similar demographic and clinical profile, including comorbidities and concomitant medications. After exclusions and matching, the final cohorts contained 19,770 patients per group, well balanced on the measured baseline covariates. The researchers then tracked five outcomes over one and two years: diabetic foot ulcer, lower-extremity amputation, osteomyelitis of the foot or ankle, Charcot neuroarthropathy, and all-cause mortality. Time-to-event analyses employed Kaplan–Meier curves and Cox proportional hazards models, with a Bonferroni correction setting the threshold for statistical significance at p less than 0.01 to guard against false positives across multiple comparisons.

The headline result concerned foot ulcers, the most common entry point into the cycle of neuropathic foot disease. At one year, 2.2 percent of GLP-1 receptor agonist users had been diagnosed with a diabetic foot ulcer compared with 2.7 percent of DPP-4 inhibitor users, corresponding to a hazard ratio of 0.813 with a 95 percent confidence interval of 0.716 to 0.922. In practical terms, the GLP-1 group experienced roughly a 19 percent relative reduction in ulcer risk over the first year. All-cause mortality was also lower in the GLP-1 group, a finding the authors interpreted as hypothesis-generating rather than definitive, given the observational design and the possibility of residual confounding.

Not every result favored the newer drugs. The apparent survival advantage and ulcer reduction came alongside an unexpected signal: Charcot neuroarthropathy occurred in 0.3 percent of GLP-1 users versus 0.2 percent of DPP-4 inhibitor users, a hazard ratio of 1.993 with a confidence interval of 1.297 to 3.064, meaning nearly a doubling of risk that reached statistical significance. By contrast, rates of lower-extremity amputation, at 0.5 percent in both groups, and foot or ankle osteomyelitis, at 0.4 percent in both groups, were indistinguishable, with hazard ratios crossing unity comfortably.

Why might a drug that reduces foot ulcers simultaneously raise the risk of Charcot neuroarthropathy? The authors and prior literature point to several plausible mechanisms. Charcot neuroarthropathy is widely understood as an “imperfect storm”: an injury to an insensate foot triggers an exaggerated inflammatory response in which osteoclast-driven bone resorption outpaces repair, producing fractures, joint disorganization, and the classic rocker-bottom deformity. Rapid improvements in glycemic control are a recognized trigger for acute neuropathic and Charcot events, a phenomenon related to treatment-induced neuropathy of diabetes, in which abruptly normalized blood sugar provokes acute painful neuropathy and arterio-venous shunting in nerve and bone microvasculature. GLP-1 receptor agonists are potent glucose-lowering agents, and their initiation in patients with poorly controlled diabetes could reproduce this dynamic, destabilizing bone in a foot already numbed by neuropathy.

Counteracting mechanisms may explain the ulcer benefit. Experimental work has shown that GLP-1 receptor signaling exerts neuroprotective and anti-inflammatory effects on peripheral nerves. Studies in diabetic rodent models demonstrated that the GLP-1 receptor agonist exendin-4 improved experimental polyneuropathy, and research in streptozotocin-induced diabetic rats found that GLP-1 receptor activation ameliorated nerve dysfunction by damping the p38 MAPK and nuclear factor kappa-B inflammatory pathways. Human imaging studies have reported that GLP-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy, and a recent meta-analysis in the Journal of Neurochemistry concluded that the class shows favorable effects on diabetic peripheral neuropathy overall. Independent of nerves, GLP-1 signaling appears to accelerate wound repair: liraglutide facilitated keratinocyte migration and healing through the PI3K/Akt pathway, exendin-4 accelerated diabetic wound closure in surgical models, and recent reviews describe GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic wounds, partly through vascular endothelial growth factor signaling. Fewer ulcers and better healing would naturally translate into fewer deep infections, which is consistent with the similar osteomyelitis rates despite different ulcer trajectories.

The findings land in a contentious literature. Previous emulated target trials have produced divergent results: one published in Diabetes Care comparing GLP-1 receptor agonists with SGLT2 inhibitors found differential amputation outcomes between classes, while another in Annals of Internal Medicine examined sodium-glucose cotransporter-2 inhibitors against GLP-1 receptor agonists for diabetic foot disease with mixed conclusions. A pharmacological database study in Diabetes, Obesity and Metabolism examined incretin-based therapy and foot ulcer risk broadly, and a nationwide observational study in Diabetes Care reported that GLP-1 receptor agonists were associated with reduced mortality after diabetic foot ulcers. The new Journal of Neurology analysis is among the first to focus specifically on patients who already have neuropathy—the population at highest risk—and the first in this context to surface Charcot neuroarthropathy as a comparative safety signal between incretin classes.

The authors are careful about causality. As a retrospective cohort study of administrative coding data, the analysis cannot prove that GLP-1 receptor agonists caused fewer ulcers or more Charcot feet. Unmeasured confounding remains possible despite propensity matching; physicians may preferentially prescribe GLP-1 receptor agonists to patients deemed healthier or more adherent, a phenomenon known as channeling bias that has been documented in glucose-lowering drug studies. Coding of Charcot neuroarthropathy is uncommon and inconsistently applied, and although the doubling of risk reached the corrected significance threshold, the absolute numbers were small—roughly three additional cases per thousand patients per year. The modest absolute reduction in ulcers, about five additional ulcer-free patients per thousand at one year, likewise requires context.

Even so, the study carries practical messages. For the growing population of patients with type 2 diabetes and established neuropathy, GLP-1 receptor agonist therapy appears, on balance, favorable for foot health, reinforcing their established cardiovascular and mortality benefits rather than undermining them. But clinicians initiating these potent glucose-lowering agents in patients with preexisting nerve damage should remain alert to the rare possibility of rapid glycemic improvement triggering neuropathic worsening or Charcot joint destruction. The authors emphasize that vigilant foot surveillance during therapy, including prompt evaluation of warmth, swelling, or deformity in an insensate foot, is warranted. Charcot neuroarthropathy caught early can be treated with offloading and immobilization before irreversible deformity sets in; caught late, it is a leading cause of amputation. As GLP-1 receptor agonists continue their meteoric rise from injectable diabetes drugs to near-universal metabolic therapy, this study is a reminder that even celebrated drugs demand close study of their effects on the body’s most vulnerable territories—and that the diabetic foot, more than most, keeps score.

Diabetic peripheral neuropathy, or DPN, is one of the most common chronic complications of diabetes. Persistently elevated blood glucose can damage peripheral nerves through several overlapping biological processes, including oxidative stress, impaired microvascular blood flow and abnormal metabolism within nerve cells. The longest nerves are generally affected first, which is why symptoms often begin in the toes and feet before moving upward in a “stocking” pattern. Patients may experience burning, electric-shock sensations, pins and needles, numbness, exaggerated sensitivity to touch or an inability to feel injuries. Because sensory feedback is disrupted, a minor wound can go unnoticed and develop into a serious ulcer. Pain and altered sensation can also interfere with walking, sleep, employment, social roles and emotional well-being.

Existing treatments for painful DPN typically combine improved diabetes management with medicines that target nerve pain, such as certain anticonvulsants, antidepressants or topical therapies. These approaches can reduce symptoms for some patients, but their effects are often incomplete, and adverse reactions may include dizziness, drowsiness, gastrointestinal problems or other complications. Nerve damage itself may not be reversed by symptom control. That has driven interest in non-drug approaches, including psychological therapies, exercise and mindfulness-based interventions, or MBIs. Mindfulness is not simply “thinking positively” or attempting to empty the mind. It is a trainable form of attention in which a person deliberately notices present-moment sensations, thoughts and emotions with less automatic judgment or avoidance. Programs may use breathing exercises, body scans, gentle movement and guided observation of pain.

The biological rationale for using mindfulness in chronic pain is different from the rationale for treating the underlying neuropathy. Mindfulness cannot restore damaged axons or directly normalize blood glucose. It may, however, influence how the nervous system processes and responds to unpleasant sensations. Pain is shaped not only by incoming signals from injured tissue but also by attention, threat appraisal, emotional distress, sleep and central nervous-system modulation. When a painful sensation is interpreted as an immediate danger, anxiety and muscle tension can amplify suffering, creating a feedback loop that makes symptoms feel more intrusive. Mindfulness training aims to help patients distinguish the raw sensory experience from the additional fear, catastrophic interpretation and behavioral restriction that can surround it. Earlier research in diabetes and chronic pain has reported potential benefits for distress and quality of life, but evidence specific to DPN remains limited.

To investigate why MBIs are rarely implemented among people with DPN, Qing Fan and colleagues at the First Affiliated Hospital of Dalian Medical University in China conducted a descriptive qualitative study with a phenomenological orientation. The researchers purposively recruited 14 patients who met the study’s inclusion criteria and conducted semi-structured, in-depth interviews. Rather than measuring pain scores before and after a treatment, phenomenological research examines how people experience and make sense of a condition or intervention. The interviews were analyzed using Colaizzi’s seven-step method, which involves extracting significant statements, formulating meanings, organizing them into themes and returning to participants’ accounts to ensure that the interpretation reflects their experiences. Member checking and peer debriefing were used to strengthen credibility, while the protocol received ethics approval and all participants provided written consent.

The analysis produced three core themes and seven subthemes. The first was psychological anxiety arising from physiological symptoms. Participants described the combined burden of chronic disease, persistent discomfort and uncertainty about whether their current treatment was working. DPN does not occur in isolation: patients must often monitor glucose, take medicines, attend appointments, adjust their diet and respond to other diabetes complications while coping with sensations that can be invisible to family members and clinicians. Changes in physical ability may alter employment, caregiving and household responsibilities, creating therapeutic stress as social roles shift. Dissatisfaction with symptom relief can further erode motivation, particularly when a new intervention appears to demand effort without offering a guaranteed result.

The second theme concerned how patients understood and accepted mindfulness. Some participants appeared to associate it with religious practice, passive relaxation or a technique that should produce immediate symptom elimination. Such assumptions matter because mindfulness-based care is usually cumulative: its proposed benefits depend on repeated practice, improved awareness and changes in the relationship to symptoms rather than an instant anesthetic effect. A person who expects the first session to remove burning pain may quickly conclude that the intervention has failed. Others may fear that mindfulness implies their pain is psychological or that clinicians are dismissing the biological basis of nerve injury. The researchers therefore identify patient education as a central implementation requirement. Explaining the difference between changing pain perception and repairing nerve damage could prevent both unrealistic expectations and the stigma associated with mental-health care.

The third theme revealed differentiated expectations about how mindfulness should be delivered and what it should accomplish. Patients did not necessarily want the same program, schedule or outcome. Some may prioritize better sleep and emotional stability, while others are more concerned with walking, daily function or coping during severe pain. Preferences may also vary between face-to-face instruction, brief home exercises, telephone support and digital delivery through an application. A long, standardized course may be unrealistic for someone working irregular hours, managing mobility problems or traveling a considerable distance for hospital care. Digital tools could provide short guided sessions, reminders and progress tracking, but the study also highlights the digital divide: access to smartphones, reliable internet, technical confidence and private space cannot be assumed. Technology may widen disparities unless programs include low-bandwidth, offline or non-digital alternatives.

The researchers describe a core contradiction between patients’ disease-management needs and their actual life circumstances. People with DPN may be highly motivated to reduce suffering but have limited time, money, transportation, family support or energy. Pain itself can make sitting still or focusing on the body difficult, especially when numbness and hypersensitivity alternate. Anxiety and frustration can undermine adherence, while social and economic pressures compete with practice. These findings shift attention away from blaming patients for “noncompliance” and toward contextualized care. A viable intervention might begin with several minutes of practice rather than an hour, offer adaptations for foot pain and mobility limitations, provide instruction in ordinary clinical settings and involve family members when appropriate. It could also connect mindfulness with established foot-care education, physical activity and psychological support rather than presenting it as a stand-alone solution.

The study’s conclusions point toward a multidisciplinary implementation pathway involving diabetologists, neurologists, nurses, psychologists, physiotherapists and digital-health specialists. A DPN-specific program would need to be tested—not merely assumed effective—in properly designed clinical trials that measure pain intensity, sleep, mood, physical function, diabetes distress, quality of life and possibly glycemic outcomes. Researchers would also need to monitor adverse experiences and determine which patients benefit, how much practice is required and whether gains persist. Because this initial study involved only 14 patients from a single tertiary hospital, its themes cannot be treated as representative of every person with DPN or as proof that mindfulness improves neuropathy. It was not preregistered, and no dataset was generated or analyzed for public release. Still, the findings offer a potentially important lesson for viral wellness culture and clinical medicine alike: an intervention’s promise is only as strong as its fit with patients’ lives. For people whose nerves are damaged and whose daily routines are already overloaded, making mindfulness accessible may be as important as making it scientifically credible.

Subject of Research: Barriers and facilitators affecting the adoption of mindfulness-based interventions among patients with diabetic peripheral neuropathy

Article Title: Barriers and Facilitators to Mindfulness-Based Interventions in Diabetic Peripheral Neuropathy: A Qualitative Inquiry to Inform Intervention Design

Article References: Fan, Q., Zhang, W., Liu, Y. et al. “Barriers and Facilitators to Mindfulness-Based Interventions in Diabetic Peripheral Neuropathy: A Qualitative Inquiry to Inform Intervention Design.” Mindfulness (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s12671-026-02969-6

Keywords: diabetic peripheral neuropathy, mindfulness-based intervention, chronic pain, diabetes distress, qualitative research, implementation science, patient-centered care, digital health

Diabetic peripheral neuropathy is a common and challenging consequence of chronic diabetes, characterized by progressive damage to peripheral nerves that leads to sensory deficits, pain, and motor dysfunction. Despite its high prevalence, affecting roughly half of all diabetic patients over time, the pathogenesis of DPN remains incompletely understood. Traditional explanations have focused on hyperglycemia-induced metabolic and vascular changes, yet growing evidence suggests immunological and inflammatory components also play crucial roles. This new study spearheaded by Yao, Wang, Zhang, and colleagues focuses on the often-overlooked contribution of mast cells, immune cells known for their roles in allergy and inflammation, to the neuropathic disease process.

Mast cells reside throughout peripheral tissues, including skin and nerve environments, where they act as sentinels responding to diverse physiological and pathological stimuli. Upon activation, these cells release a potent cocktail of inflammatory mediators such as histamine, cytokines, and proteases. In the diabetic context, the researchers found that the “diabetic milieu”—characterized by elevated glucose levels, advanced glycation end products (AGEs), and pro-inflammatory factors—induces dysregulated mast cell activation. This heightened activity leads to an exaggerated inflammatory state within the peripheral nervous system, promoting nerve damage and hindering repair mechanisms.

Through state-of-the-art in vivo experimentation in mouse models of diabetes, the team meticulously demonstrated that mast cell hyperactivation correlates with worsening neuropathic symptoms. Behavioral assays uncovered amplified pain sensitivity and nerve conduction impairments parallel to increased mast cell density and degranulation near peripheral nerves. Cellular and molecular analyses unveiled elevated levels of mast cell-derived inflammatory mediators, which disrupted the homeostasis of neuronal microenvironments, exacerbating oxidative stress and microvascular dysfunction. This multifactorial assault contributes to progressive axonal degeneration and myelin sheath deterioration, hallmarks of DPN pathology.

What sets this study apart is its integrated mechanistic approach combining immunology, neurobiology, and metabolic science. By employing genetic and pharmacological interventions to modulate mast cell activity, the researchers were able to significantly attenuate neuropathic symptoms. For instance, mice treated with mast cell stabilizers or genetically engineered to have impaired mast cell function exhibited reduced nerve inflammation, enhanced nerve fiber density, and improved sensory responses compared to untreated diabetic controls. These results suggest that mast cells are not mere bystanders but active mediators that amplify diabetic nerve injury.

The biochemical pathways identified involve intercellular signaling cascades where mast cell-derived tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and other cytokines influence peripheral nerve Schwann cells and endothelial cells. This pro-inflammatory milieu disrupts normal nerve blood flow, increases vascular permeability, and triggers recruitment of additional immune cells. Moreover, the oxidative stress induced by mast cell mediators damages mitochondrial function within axons, compounding neurodegeneration. The cross-talk between immune and neural cells unveiled by the data reveals new targets for therapeutic intervention, particularly in modulating immune responses to protect nerve integrity.

Clinically, these findings carry profound implications. Current DPN management predominantly focuses on glycemic control and symptomatic pain relief, with limited options to halt or reverse nerve damage. The study’s insights highlight mast cells as a promising target for disease-modifying therapies. Mast cell stabilizers, commonly used for allergic conditions, could be repurposed or optimized to reduce neuroinflammation in diabetic patients. Additionally, biomarkers of mast cell activation may serve as valuable tools for early diagnosis and monitoring of neuropathy progression, facilitating personalized treatment strategies.

This research also encourages reevaluation of the broader role of immune system dysregulation in diabetic complications. Mast cells may represent only one component of a complex immunopathogenic network involving macrophages, T cells, and resident glial cells contributing to nerve injury. Understanding the interplay among these cells and the metabolic disturbances of diabetes will be key to developing comprehensive therapies. Furthermore, the diabetic milieu’s impact on mast cell plasticity and phenotype warrants deeper exploration, as it may reveal how chronic metabolic stress reprograms immune function.

The utilization of advanced imaging techniques and single-cell transcriptomics in this study allowed unprecedented resolution of mast cell behavior within affected tissues. Such technological advancements enable researchers to unravel cellular heterogeneity and dynamics in disease states, accelerating discovery. This precision approach exemplifies how cutting-edge methodology can elucidate complex disease mechanisms that were previously inaccessible. The integration of physiological, molecular, and computational analyses sets a new standard for translational neuroscience research.

From a translational perspective, the use of mouse models provides essential proof-of-concept data yet also underscores the need for validation in human tissues and clinical trials. Differences in mast cell biology between species mean cautious interpretation is necessary before clinical application. However, the conservation of key inflammatory pathways suggests that therapeutic modulation of mast cell activity holds promise. Ongoing studies investigating mast cell inhibitors in diabetic cohorts will help determine efficacy and safety in patients with DPN.

Beyond diabetic neuropathy, the implications of this study extend to other neuroinflammatory diseases where mast cells could play a pathological role. Conditions such as multiple sclerosis, fibromyalgia, and chronic pain syndromes may also involve dysregulated mast cell responses. The researchers’ findings provide a framework for examining mast cell contributions to diverse neurological disorders, potentially broadening the impact of this new knowledge. Cross-disciplinary collaborations will be essential to translate these insights across fields of medicine.

In summary, this seminal study by Yao and colleagues represents a major advance in understanding the immunological underpinnings of diabetic peripheral neuropathy. By demonstrating that diabetic conditions cause maladaptive mast cell activation, which accelerates nerve damage, the research identifies novel cellular and molecular targets for intervention. These discoveries open the door to innovative therapeutic approaches that could transform care for millions suffering from debilitating neuropathic complications of diabetes. The work exemplifies the power of mechanistic research in illuminating complex chronic diseases and fueling hope for better outcomes.

As diabetes incidence continues to surge globally, so too does the urgency of addressing its complications like DPN that impose substantial human and economic burdens. Research at the intersection of immunology and neurobiology, as exemplified herein, offers promising avenues for breakthrough treatments. Continued exploration of mast cell biology in diabetic contexts may yield more precise and effective strategies to preserve nerve function and enhance quality of life for patients worldwide. This study is an important milestone in that journey.

Future investigations will need to delineate the exact molecular triggers of mast cell dysregulation in diabetic environments and determine long-term effects of modulating mast cell activity. Understanding how hyperglycemia, lipid abnormalities, and oxidative stress collectively influence mast cell phenotype will deepen insight. Integrating these data with large-scale clinical studies could eventually lead to mast cell-related biomarkers and new classes of therapeutics specifically designed for DPN. The potential to alter the trajectory of diabetic neuropathy by targeting immune cells heralds a paradigm shift in treatment.

The findings decisively clarify that diabetic neuropathy is not merely a metabolic or vascular disease but a complex neuroimmune disorder involving maladaptive cross-talk between immune and nervous systems. Inclusive, multidisciplinary approaches grounded in this understanding are critical to overcoming current therapeutic limitations. The study sets a compelling precedent for harnessing immunomodulation to combat chronic neuropathic diseases linked to diabetes and beyond. It is a call to action for researchers and clinicians alike to pursue innovation in this promising frontier.

Subject of Research: Dysregulated mast cell activation and its role in diabetic peripheral neuropathy progression under diabetic conditions in mice.

Article Title: Dysregulated mast cell activation induced by diabetic milieu exacerbates the progression of diabetic peripheral neuropathy in mice.

Article References:
Yao, X., Wang, X., Zhang, R. et al. Dysregulated mast cell activation induced by diabetic milieu exacerbates the progression of diabetic peripheral neuropathy in mice. Nat Commun 16, 4170 (2025). https://doi.org/10.1038/s41467-025-59562-z

Image Credits: AI Generated